Niagen Bioscience, Inc.
- Last sale
- Nov 12, 2026 · +2.39%
- Market cap
- $169.48M
- 79.2M shares
- Filings
- 981
Q3 2026+29.9% FY25 yoy
Q3 2026+103.3% FY25 yoy
Q3 2026+110.7% FY25 yoy
Q3 2020derivedN/M FY19 yoy
Q3 2026+81.8% FY25 yoy
Q3 2026+45.6% FY25 yoy
- $169.48M
- 16.6×
- 1.4×
- 2.0×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $129,423,000 | reported | |
| FY 2024 | 2024-12-31 | $99,597,000 | reported | |
| FY 2023 | 2023-12-31 | $83,570,000 | reported | |
| FY 2022 | 2022-12-31 | $72,050,000 | reported | |
| FY 2021 | 2021-12-31 | $67,449,000 | reported | |
| FY 2020 | 2020-12-31 | $59,257,000 | reported | |
| FY 2019 | 2019-12-31 | $46,291,000 | reported | |
| FY 2018 | 2018-12-31 | $31,557,000 | reported | |
| FY 2017 | 2017-12-30 | $21,201,000 | reported | |
| FY 2016 | 2016-12-31 | $21,664,648 revised | reported | |
| FY 2015 | 2016-01-02 | $17,884,886 revised | reported | |
| FY 2014 | 2015-01-03 | $15,313,179 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $251.00K | $251.00K | — | 80.08M sh | +3.0% | — |
| FY2024 | — | $0.00 | $0.00 | — | 77.75M sh | +3.2% | — |
| FY2018 | — | $404.00K | $404.00K | — | 55.29M sh | +0.8% | — |
| FY2017 | — | $0.00 | $0.00 | — | 54.84M sh | +44.7% | — |
| FY2012 | — | $8.20K | $8.20K | — | 96.51M sh | +6.1% | — |
Segments
Segments
LineFY2025ShareChange
Consumer Products segment$97.67M75%+27.2%
Ingredients segment$28.68M22%+44.7%
Analytical Reference Standards and Services segment$3.08M2.4%+2.2%
Pharmaceuticals segment$0.00——
Corporate and Other Segment———
Total$129.42M
Medicinal chemicals & botanical products
Niagen Bioscience, Inc. is the 13th largest of the 41 covered companies the SEC files under this code, by revenue. SIC 2833
CompanyRevenueGrowthNet marginMarket cap
JUSHJushi Holdings Inc.$262.9M2.1%26.1%$103.8MBTMDbiote Corp.$192.2M2.5%14.1%$37.1MGLASGlass House Brands Inc.$182.0M9.4%16.3%—MRMDMarimed Inc.$159.8M1.3%9.1%$20.2MCRONCronos Group Inc.$146.6M24.6%6.4%$1.3BNAIINatural Alternatives International Inc$142.5M9.7%14.5%$7.0M
NAGENiagen Bioscience, Inc. (this company)$129.4M29.9%13.4%$169.5M
MTEXMannatech Inc$108.0M8.3%14.1%$13.1MLEEEFLeef Brands Inc.$34.8M22.1%50.7%$42.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR